Consensus Novavax, Inc.

Stocks

NVAX

US6700024010

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2026-07-31 EDT			5-day change	1st Jan Change
7.320 ^USD	-1.61%		-1.88%	+8.93%

06-29	Novavax, Inc.(NasdaqGS:NVAX) dropped from Russell Small Cap Comp Growth Benchmark	CI
06-29	Novavax, Inc.(NasdaqGS:NVAX) dropped from Russell 2500 Growth Benchmark	CI

Evolution of the Average Target: Novavax, Inc.

Evolution of the Target Price: Novavax, Inc.

Changes in Analyst Recommendations: Novavax, Inc.

1fa708bd7a8c199e1ffec83e370b5dbe.37oWn2cYb836e-HifCJMRc2fk9e8JgUFcmaaLnRcyyI.jftJ9QJPX7mpGNmxLGcPC_vr4ZTwak43HBP2XDopuRC98E_TL0FY-Zwckg~b00520670a5152783e326032fe3a18d2

Analysts' recommendations: Novavax, Inc.

04-09	B. Riley Raises Price Target on Novavax to $18 from $16, Keeps Buy Rating	MT
11-11	B. Riley Adjusts Price Target on Novavax to $16 From $18, Maintains Buy Rating	MT
11-10	B. Riley Adjusts Price Target on Novavax to $16 From $18, Maintains Buy Rating	MT
25-08-20	Novavax: BofA downgrades stock
25-08-20	Novavax Faces 'Increasingly Murky' Outlook on Vaccine Uncertainties, BofA Securities Says	MT
25-08-20	BofA Downgrades Novavax to Underperform From Neutral, Adjusts Price Target to $7 From $9	MT
25-08-20	BofA Securities Downgrades Novavax to Underperform From Neutral, Price Target is $7	MT
25-05-05	B. Riley Cuts Price Target on Novavax to $18 From $22, Keeps Buy Rating	MT
25-02-28	BTIG Initiates Novavax at Buy With $19 Price Target	MT
24-11-18	B. Riley Adjusts Novavax Price Target to $22 From $26, Maintains Buy Rating	MT
24-10-16	Jefferies Cuts Novavax's Price Target to $25 From $31, Buy Rating Maintained	MT
24-10-10	B. Riley Raises Price Target on Novavax to $26 From $23, Keeps Buy Rating	MT
24-08-12	B. Riley Adjusts Price Target on Novavax to $23 From $25, Maintains Buy Rating	MT
24-08-02	B. Riley Adjusts Price Target on Novavax to $25 From $29, Maintain Buy Rating	MT
24-07-30	Novavax Shares Sink After JPMorgan Downgrades Rating to Underweight From Neutral	MT
24-07-30	JPMorgan Downgrades Novavax to Underweight From Neutral, Adjusts Price Target to $8	MT
24-05-23	B. Riley Boosts Price Target on Novavax to $29 From $11, Maintains Buy Rating	MT
24-03-01	HC Wainwright Cuts Price Target on Novavax to $19 From $35, Keeps Buy Rating	MT
24-02-23	B. Riley Trims Novavax's PT to $11 From $12 After Reaching Settlement on Gavi Arbitration Dispute, Keeps Buy Rating	MT
23-12-14	Novavax: green light for updated Covid vaccine in Sweden
23-11-10	B. Riley Lowers Novavax's Price Target to $12 From $15 After Near-Term COVID-19 Sales Estimate Revisions, Maintains Buy Rating	MT
23-08-09	B. Riley Upgrades Novavax to Buy From Neutral After Above-Consensus Q2 Beat, Says Turnaround Progressing; Retains $15 PT	MT
23-05-10	B. Riley Raises Novavax's PT to $15 From $10, Says Q1 Financial Update 'Not As Bad As Feared'; Keeps Neutral Rating	MT
23-03-01	B. Riley Downgrades Novavax to Neutral From Buy, Lowers Price Target to $10 From $29	MT
23-02-17	B. Riley Cuts Novavax's Price Target to $29 From $37, Maintains Buy Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	NOVAVAX, INC.					+92.81%
	LONZA GROUP AG					+21.08%
	REVOLUTION MEDICINES, INC.					+10.38%
	IQVIA HOLDINGS INC.					+16.14%
	BEONE MEDICINES AG					+31.53%
	CELLTRION, INC.					+42.05%
	MEDPACE HOLDINGS, INC.					+0.82%
	ASCENDIS PHARMA A/S					+24.82%
	EUROFINS SCIENTIFIC SE					+6.41%
	ICON PUBLIC LIMITED COMPANY					+13.45%
	Average					+25.95%
	Weighted average by Cap.					+20.68%